Physician profile
Ronald Kahn
NPI 1508843079
$4,267.51
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,310 · 2020: $597 · 2021: $840 · 2022: $521.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,271.91 | 2019-2022 | |
| Pfizer INC. | $672.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $460.52 | 2019-2021 | |
| Amarin Pharma, INC. | $301.51 | 2019-2021 | |
| Amgen INC. | $209.60 | 2019-2020 | |
| Novo Nordisk INC | $209.12 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.42 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $189.78 | 2022 | |
| Sanofi-Aventis U.S. LLC | $136.83 | 2019-2021 | |
| Lilly USA, LLC | $118.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $73.19 | 2019-2021 | |
| Abbvie INC. | $71.26 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $64.17 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.96 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.76 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $52.11 | 2019 | |
| Astellas Pharma US INC | $36.63 | 2019 | |
| Mylan Specialty L.P. | $18.69 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.33 | 2020 | |
| Horizon Therapeutics Plc | $14.93 | 2019 | |
| Circassia INC. | $13.43 | 2019 | |
| Abbott Laboratories | $12.86 | 2020 | |
| Allergan, INC. | $11.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.